Palatin Technologies, Inc. (AMEX: PTN) was founded in 1986 and is headquartered in Cranbury, New Jersey, USA, with 19 full-time employees. It is a biopharmaceutical company that develops targeted receptor-specific therapeutics in the United States for Treat various diseases.
Palatin Technologies, Inc. (PTN):
Palatin Technologies, Inc. is a professional biopharmaceutical company that develops first-class drugs based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential.
Palatin Technologies’ main product is Vyleesi, an on-demand subcutaneous injection product, which has completed phase III clinical studies for the treatment of premenopausal women with acquired systemic hyposexuality disorder. Vyleesi™ is the trade name of Bremelanotide, which is used to treat hypoactive sexual desire disorder (HSDD). The US Food and Drug Administration (FDA) is approving Vyleesi’s new drug application. Palatin Technologies has authorized the North American rights of Vyleesi to AMAG Pharmaceuticals, Inc., the Chinese rights to Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. and the Korean rights to Kwangdong Pharmaceutical Co., Ltd..
Palatin Technologies’ drug development program also includes programs for the melanocortin receptor system, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel disease; and PL-8331, a Preclinical drug candidates for the treatment of ocular inflammation, as well as melanocortin receptor 4 peptides and orally active small molecules for the treatment of genetic metabolism and obesity.
Palatin Technologies has developed a natriuretic peptide receptor system, which contains the natriuretic peptide receptor-A agonist PL3994, which has completed phase I clinical studies for the treatment of cardiovascular indications; and PL-5028, one A dinatriuretic peptide receptor A and C agonist for pre-clinical development of cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis.